Literature DB >> 3997787

Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.

J P Feighner, J Herbstein, N Damlouji.   

Abstract

Patients with "treatment resistant" depression who do not respond to standard methods or relapse over time have a moral and legitimate right to innovative therapy. Combined treatment with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and stimulants has been resisted by practitioners because of hypertensive and hyperthermic crises noted in certain cases. This paper reports a case series demonstrating the safety and efficacy of adding a stimulant to an MAOI or to a combination of TCA and MAOI in the treatment of intractable depression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997787

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.

Authors:  Joshua A Israel
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-10

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Authors:  Rachael W Taylor; Lindsey Marwood; Emanuella Oprea; Valeria DeAngel; Sarah Mather; Beatrice Valentini; Roland Zahn; Allan H Young; Anthony J Cleare
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 4.  Adjunctive therapy in patients with Alzheimer's disease. A practical approach.

Authors:  J Corey-Bloom; D Galasko
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

Review 5.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.

Authors:  I Schweitzer; V Tuckwell
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

7.  Drug treatment of phobias. Efficacy and optimum use.

Authors:  A P Levin; M R Liebowitz
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

8.  Psychostimulants in the therapy of treatment-resistant depression Review of the literature and findings from a retrospective study in 65 depressed patients.

Authors:  G Stotz; B Woggon; J Angst
Journal:  Dialogues Clin Neurosci       Date:  1999-12       Impact factor: 5.986

9.  Triple reuptake inhibitors: a premise and promise.

Authors:  David M Marks; Chi-Un Pae; Ashwin A Patkar
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

10.  Triple reuptake inhibitors: the next generation of antidepressants.

Authors:  David M Marks; Chi-Un Pae; Ashwin A Patkar
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.